MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability -January 30, 2024 at 02:52 am EST

EQS-News: MorphoSys AG


/ Key word: Forecast





MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

Related Keywords

United States ,Boston ,Massachusetts ,Germany ,Canada ,Planegg ,Bayern ,Julia Neugebauer ,Thomas Biegi ,Jean Paul Kress ,Eamonn Nolan ,Drug Administration ,Xencor Inc ,European Medicines Agency ,Corporate Affairs ,Constellation Pharmaceuticals Inc ,Corporate Communications Investor Relations ,Nasdaq ,Linkedin ,Exchange Commission ,Twitter ,Lymphoma Society ,Sys Reports Preliminary ,Product Sales ,Gross Margin ,Reduces Financial ,Chief Executive Officer ,Morphosy Phase ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Prescribing Information ,Morphosy Annual Report ,Vice President ,Global Investor ,Corporate Communications ,Markets ,